Topics

Latest "Acer Therapeutics Announces Acceptance Priority Review EDSIVO Treatment" News Stories

06:12 EST 25th February 2020 | BioPortfolio

Here are the most relevant search results for "Acer Therapeutics Announces Acceptance Priority Review EDSIVO Treatment" found in our extensive news archives from over 250 global news sources.

More Information about Acer Therapeutics Announces Acceptance Priority Review EDSIVO Treatment on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Acer Therapeutics Announces Acceptance Priority Review EDSIVO Treatment for you to read. Along with our medical data and news we also list Acer Therapeutics Announces Acceptance Priority Review EDSIVO Treatment Clinical Trials, which are updated daily. BioPortfolio also has a large database of Acer Therapeutics Announces Acceptance Priority Review EDSIVO Treatment Companies for you to search.

Showing "Acer Therapeutics Announces Acceptance Priority Review EDSIVO Treatment" News Articles 1–25 of 34,000+

Tuesday 25th February 2020

Axonics® to Present at the Barclays Global Healthcare Conference

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Executive Officer Raymond W. Cohen is scheduled for a fireside chat at the Barclays Global Healthcare Conference, Tuesday...


Peptilogics Announces CARB-X Funding to Accelerate Development of First-in-Class Antibiotics to Address the Global Threat of Multi-drug Resistant Bacteria

CARB-X Award Worth up to $12.17M USD to Develop Peptilogics’ Lead Compound in Prosthetic Joint Infection and Accelerate Development of Additional Novel Antibiotics Peptilogics, a clinical-stage biotechnology company developing a computational peptide therapeutics discovery platform and no

Novartis launches review into safety of eye drug Beovu

Novartis has launched an external review into the safety of its blindness medicine Beovu after the American Society of Retinal Specialists (ASRS) raised concerns.


Cancer treatment co Kahr Medical raises $18m

The round was led by Flerie Invest AB, Oriella Limited, Hadasit Bio-Holdings, Pavilion Capital, and Mirae Asset Venture Investment.

ImmunOs Therapeutics Selects ProBioGen for Development and Large-Scale Manufacturing Services

    BERLIN, Germany and SCHLIEREN, Switzerland, February 25, 2020 / B3C newswire / -- ProBioGen AG today announced that ImmunOs Therapeutics AG has signed a Manufacturing Services Agreement for their novel platform of multitasking

Kurin, Inc. Receives FDA 510k Clearance for Its Push-Button Needle

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, has received 510(k) clearance (k191832) for its novel push-button needle. “The FDA clearance of our push-button needle is another important step in the continued growth of our company,” said Bob Rogers, CEO of Kurin. “Development of our proprietary needle provides us vertical integration and...

Shionogi’s FETROJA now available for treatment of complicated urinary tract infections in US

FETROJA, which was approved by the U.S. Food and Drug Administration on November 14, 2019, is the first approved antibiotic that functions as a siderophore and has the The post Shionogi’s FETROJA now available for treatment of complicated urinary tract infections in US appeared first on Pharmaceutical Business review.

Matrix Metalloproteinase 9 Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

Matrix Metalloproteinase 9 Pipeline Review, H2 2019SummaryMatrix Metalloproteinase 9 Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35 Matrix metallopeptidase 9 MMP9 is a matrixin that belong to the zincmetalloproteinases family. It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resor...

GM Pharm announces health items for sale on Rakuten, popular items featured

The GM Pharm, specializing in health items made by pharmacists, is having a discount event SEOUL, South Korea, Feb. 25, 2020 /PRNewswire/ -- GM Pharm announced that it would be selling popular items on Rakuten for a 20% discount. Included in the sales list are The Probiotics for Woman, The rTG Omega-3, The Folic for Daddy, and The Folic for Mommy.

Global Laboratory Information Management System (LIMS) Market 2020-2024 | Growing Demand for Bio-Banking to Boost Market Growth | Technavio

The laboratory information management system market is expected to grow by USD 705.85 million during 2020-2024, according to the latest market research report by Technavio. Request a free sample report This press release features multimedia. View the full release here: https://www.business

Warriors Heart highlights Beyond 12 Step Solutions in TIME Special Edition The Science of Addiction

To find new ways to help individuals struggling with addiction that go beyond 12-step programs in 2020 and beyond, Warriors Heart’s CD Team Lead Vonnie Nealon, CFRC, outlines the evidence-based modalities their clinicians use to heal warriors (military, veterans and first responders) in the latest TIME Special Edition: The Science of Addiction (2019). SAN ANTONIO (PRWEB) February 25, 2020 Warri...

IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor 79% of evaluable patients achieved disease control on target lesions; 53% experienced tumor regressions 37% achieved durable clinical benefit lasting ≥ 6 months; including four partial regressions so far, overall response rate not yet reached as six patients remain on treatment Treatment well-tolera...

GSK, Clover collaborate to assess protein-based coronavirus vaccine candidate

Under the research collaboration, the companies will evaluate Clover’s protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) with GSK’s pandemic adjuvant system. GSK’s pandemic adjuvant system will help further assess The post GSK, Clover collaborate to assess protein-based coronavirus vaccine candidate appeared first on Pharmaceutical Business review.

iaedp™ Symposium Reveals Critical Differences Between Binge Eating Disorder and Emotional Eating

In the interactive workshop, “Binge Eating Disorder Vs. Emotional Eating: When Do We Treat “Overeating”? -- participants will learn how to effectively treat binge eating disorder while supporting clients to have a healthy relationship with food, which may include emotional eating as an appropriate response to life circumstances. Now in its 35th year, the 2020 iaedp™ Symposium will be hel...

San Francisco Dental Implant Center Announces Post on Perils of So-called 'Cheap Dental Implants' in the Bay Area

San Francisco Dental Implants is announcing a new post about the drawbacks of choosing 'cheap dental implants' in the Bay Area. Patients may find that cheap implants are not usually the best choice for their dental needs. SAN FRANCISCO (PRWEB) February 25, 2020 San Francisco Dental Implant Center, serving the Bay Area community with dental implants and oral surgery at https://www.sfdental...

Liva Healthcare Appoints CCO and Announces 13 Contract Wins

Liva Healthcare continues its impressive growth trajectory with the appointment of a Chief Commercial Officer (CCO) and 13 contract wins across healthcare providers, insurance and pharmaceutical organisations. This follows an investment of €8 million from three German venture funds in 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/hom...

Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial

HELSINKI, Feb. 25, 2020 /PRNewswire/ -- Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses as ...

University of Nottingham Ningbo China Researcher Helps Strengthen City’s COVID-19 Resilience

The sudden and unexpected outbreak of the novel coronavirus (COVID-19) has tested the adaptability and robustness of many Chinese cities as they rise to the challenge. Ningbo is no exception. For Dr. Ali Cheshmehzangi, Associate Professor in Architecture and Urban Design at the University of Nottingham Ningbo China, how to ensure and improve Ningbo’s virus resilience has been a priority sin...

Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA

17th patient dosed in the ongoing phase 2/3 AAVance study Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its LYS-SAF302 program for the treatment of mucopolysaccharidosis Type II...

FDA Accepts Genentech’s Biologics License Application for Fixed-dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast Cancer

— Fixed-dose combination is administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment — — The U.S. Food Drug and Administration is expected to decide on approval by October 18, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug...

Osteosarcoma Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $1700

Osteosarcoma Pipeline Review, H2 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma Pipeline Review, H2 2019, provides an overview of the Osteosarcoma Oncology pipeline landscape.Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone...

The Institute for Clinical and Economic Review, ICER, is partnering with Aetion, a startup that analyzes insurance claims and other data mostly for pharmaceutical companies. https://buff.ly/2HRd9rt 

The Institute for Clinical and Economic Review, ICER, is partnering with Aetion, a startup that analyzes insurance claims and other data mostly for pharmaceutical companies. https://buff.ly/2HRd9rt 

Monday 24th February 2020

Varicose Ulcer Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $2975

FirstView Market Insight Varicose Ulcer Market Review, Epidemiology And Market Forecast 2029 provides in depth understanding of historical and forecasted epidemiology along with the detailed market insights.The report covers detailed information on the disease, treatment algorithm, existing treatment and upcoming treatment regimens, unmet needs, market drivers, market barriers, sales trend and ...

Severe Psoriasis Pipeline Review2037 [Published by First View Insight] Prices from USD $1063

Firstview Insight's Severe Psoriasis Pipeline Review2037 provides an overview of the pipeline landscape of Severe Psoriasis It provides comprehensive insights of all the clinical and nonclinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing...

Global Allergy Immunotherapy Market Data Survey Report 20152025 [Published by HeyReport] Prices from USD $1275

SummaryAllergen immunotherapy, also known as desensitization or hyposensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an attempt to change the immune s...


Quick Search

News Quicklinks